Claims
- 1. A method for preventing or treating pulmonary insufficiency, comprising administering to a subject in need thereof an effective amount of a diaminotrifluoromethylpyridine compound or its salt, wherein said compound is represented by formula (I): whereinX is a —CW1R1 group, a —COCOR2 group, a —CW1NHCOR2 group, a —C(═W1)W2R3 group or a —CW1N(R4)R5 group; Y is an alkyl group, a —CW3R6 group, a —COCOR group, a —NHCOR7 group, a —C(═W3)W4R8 group, a —NH)mSO2R9 group, a —(NH)mSO2OR10 group or a —(NH)mSO2N(R11)R12 group; wherein each of R1, R6 and R9, which are independent of one another, is a chain hydrocarbon group which may be substituted, a monocyclic hydrocarbon group which may be substituted, a polycyclic hydrocarbon group which may be substituted, a monocyclic heterocycle group which may be substituted or a polycyclic heterocycle group which may be substituted; wherein each of R2 and R7, which are independent of each other, is an alkyl group which may be substituted, an alkoxy group which may be substituted, a phenyl group which may be substituted or a phenoxy group which may be substituted; wherein each of R3, R8 and R10, which are independent of one another, is an alkyl group which may be substituted, an alkenyl group which may be substituted, an alkynyl group which may be substituted, a cycloalkyl group which may be substituted, a phenyl group which may be substituted or a benzyl group which may be substituted; wherein each of R4, R5, R11 and R12, which are independent of one another, is an alkyl group which may be substituted; each of W1, W2, W3 and W4 which are independent of one another, is an oxygen atom or a sulfur atom; and wherein m is 0 or 1; wherein said compound of formula (I) is not a compound where one of X and Y is a —COCF2X1 group (wherein X1 is a hydrogen atom, a halogen atom, an alkyl group or a haloalkyl group), and the other is a —COCF2X2 group (wherein X2 is a hydrogen atom, a halogen atom, an alkyl group, a haloalkyl group or an alkylcarbonyl group), a —COOX3 group (wherein X3 is an alkyl group which may be substituted or a phenyl group which may be substituted) or a —COX4 group (wherein X4 is an alkyl group, a haloalkyl group, an alkenyl group, an alkynyl group, a phenyl group which may be substituted, a furanyl group or a naphthyl group).
- 2. The method of claim 1, whereinX is a —CW1R1 group or a —C(═W1)W2R3 group and Y is a —SO2R9 group.
- 3. The method of claim 1, whereinX is a —CW1R1 group or a —C(═W1)W2R3 group, R1 is an alkyl group which may be substituted, an alkenyl group which may be substituted, a cycloalkyl group which may be substituted, a cycloalkenyl group which may be substituted, a phenyl group which may be substituted, a tetrahydronaphthyl group which may be substituted, an indanyl group which may be substituted, a furanyl group which may be substituted or a thienyl group which may be substituted, R3 is an alkyl group which may be substituted, Y is a —SO2R9 group, and R9 is an alkyl group which may be substituted, an alkenyl group which may be substituted, a cycloalkyl group which may be substituted, a cycloalkenyl group which may be substituted or a phenyl group which may be substituted.
- 4. The method of claim 1, whereinX is a —CW1R1 group or a —C(═W1)W2R3 group, R1 is an alkyl group, a haloalkyl group, an alkoxycarbonyl alkyl group, an alkenyl group, a haloalkenyl group, an alkenyl group substituted with a thienyl group, a cycloalkyl group, a cycloalkyl group substituted with a halogen atom, a phenyl group, a phenyl group substituted with a halogen atom, a phenyl group substituted with an alkyl group or a haloalkyl group, a phenyl group substituted with an alkoxy group or a haloalkoxy group, a tetrahydronaphthyl group, an indanyl group, a furanyl group or a thienyl group, R3 is an alkyl group or a haloalkyl group, Y is a —SO2R9 group, and R9 is an alkyl group, a haloalkyl group, a phenyl group, a phenyl group substituted with a halogen atom, a phenyl group substituted with an alkyl group or a haloalkyl group, or a phenyl group substituted with an alkoxy group or a haloalkoxy group.
- 5. The method of claim 1, whereinX is an alkoxycarbonyl alkylcarbonyl group, an alkenylcarbonyl group, an alkenylcarbonyl group substituted with a thienyl group, a cycloalkylcarbonyl group, an indanylcarbonyl group, a thiophenecarbonyl group, a tetrahydronaphthylcarbonyl group or a benzoyl group which may be substituted with a halogen atom or a haloalkyl group, and Y is an alkylsulfonyl group.
- 6. The method of claim 1, whereinX is a cycloalkylcarbonyl group, an alkenylcarbonyl group, a thiophenecarbonyl group or a benzoyl group which may be substituted with halogen, and Y is an alkylsulfonyl group.
- 7. The method of claim 1, whereinthe diaminotrifluoromethylpyridine compound is selected from the group consisting of N-(2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl)cyclohexanecarboxamide, N-(2-methylsulfonylamino-5-trifluoromethyl-3-pyridyl)crotonamide, N-(2-methylsulfonylamino-5-trifluoromethyl-3-pyridyl)-2-thiophenecarboxamide, N-(2-methylsulfonylamino-5-trifluoromethyl-3-pyridyl)cyclopentanecarboxamide and N-(2-methylsulfonylamino-5-trifluoromethyl-3-pyridyl)-4-fluorobenzamide.
- 8. The method of claim 1, wherein the diaminotrifluoromethylpyridine compound is N-(2′-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl)cyclohexanecarboxamide.
- 9. The method of claim 1 that is a method for preventing pulmonary insufficiency.
- 10. The method of claim 1 that is a method for treating pulmonary insufficiency.
- 11. The method of claim 1, wherein said pulmonary insufficiency is a disease selected from the group consisting of acute respiratory distress syndrome and chronic obstructive pulmonary disease.
- 12. The method of claim 1, further comprising administering at least one other drug, or therapeutic agent.
- 13. The method of claim 1, comprising administering an alkaline metal salt, an alkaline earth metal salt or an organic amine salt of said compound.
- 14. The method of claim 1, comprising administering said compound perorally.
- 15. The method of claim 14, wherein said compound is formulated in a manner to be rapidly discharged, be gradually discharged, or be belatedly discharged once administered to a subject.
- 16. The method of claim 1, comprising administering said compound in the form of a tablet, capsule, powder, granule, troche, liquid, suspension, emulsion, ointment, suppository, enema, or syrup.
- 17. The method of claim 1, comprising administering said compound parenterally.
- 18. The method of claim 1, comprising administering said compound topically or by rectal administration.
- 19. The method of claim 1, comprising administering said compound via the respiratory airway or by inhalation.
- 20. The method of claim 1, comprising administering to a daily dose ranging from 0.1 mg to about 10 g of said diaminotrifluoromethylpyridine compound or its salt.
- 21. The method of claim 1, comprising administering a daily dose ranging from 1 mg to about 1 g of said diaminotrifluoromethylpyridine compound or its salt.
- 22. The method of claim 1, further comprising at least one antibacterial agent or antioxidant.
- 23. The method of claim 1, further comprising a medically acceptable buffer solution, a medically acceptable reagent, or a medically acceptable inert carrier.
Priority Claims (1)
Number |
Date |
Country |
Kind |
2000-024349 |
Feb 2000 |
JP |
|
CROSS REFERENCE TO RELATED CASES
The present application is a 371 application of PCT/JP01/00616, filed on Jan. 30, 2001, which claims priority to Japanese Application No. JP 2000-24349, filed on Feb. 1, 2000, which are hereby incorporated by reference in their entirety.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
PCT/JP01/00616 |
|
WO |
00 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO01/56570 |
8/9/2001 |
WO |
A |
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
5229403 |
Haga et al. |
Jul 1993 |
A |
5492908 |
Haga et al. |
Feb 1996 |
A |
6197796 |
Ogura |
Mar 2001 |
B1 |
Non-Patent Literature Citations (3)
Entry |
L. Touqui et al.: “A role for pholpholipase A2 in ARDS pathogenesis” Mol. Med. Today, vol. 3, pp. 244-249 1999. |
D.L. Bowton et al.: “Phospholipase A2 and arachidonate increase in bronchoalveolar lavage fluid after inhaled antigen challengein athmatics” Am. J Rtesip. Crit. Care Med., vol. 155, pp. 421-425 1997. |
L. Arbibe et al.: “Generation of lyso-phospholipids from surfactant in acute injury is mediated by type-II phospholipase A2 and inhibited by direct surfactant protein A-phospholipase A2 protein interaction” J. Clin. Invest., vol. 102, No. 6, pp. 1152-1160 1998. |